Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17525783 | 0.85 | LMNA (0.50) | LMNAPOLBALDH1A1ANPEPMEN1 | |
| SCHEMBL9807555 | 0.85 | LMNA (0.50) | LMNAPOLBALDH1A1ANPEPMEN1 | |
| SCHEMBL23602333 | 0.85 | LMNA (0.50) | LMNAPOLBALDH1A1ANPEPMEN1 | |
| SCHEMBL6278883 | 0.85 | LMNA (0.46) | LMNAPOLBALDH1A1ANPEPMEN1 | |
| SCHEMBL9231216 | 0.84 | LMNA (0.49) | LMNAPOLBALDH1A1ANPEPMEN1 | |
| SCHEMBL6278885 | 0.82 | LMNA (0.44) | LMNAPOLBALDH1A1ANPEPKMT2A | |
| SCHEMBL5956975 | 0.81 | LMNA (0.49) | LMNAPOLBALDH1A1ANPEPMEN1 | |
| SCHEMBL27048660 | 0.79 | LMNA (0.45) | LMNAPOLBALDH1A1ANPEPMEN1 | |
| SCHEMBL24393531 | 0.79 | LMNA (0.45) | LMNAPOLBALDH1A1ANPEPMEN1 | |
| SCHEMBL19125739 | 0.79 | LMNA (0.45) | LMNAPOLBALDH1A1ANPEPMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177883-A1 | Antisense Oligonucleotides Targeting ATXN3 | HOFFMANN-LA ROCHE INC. | 2022-06-09 | — | — | US | disclosed |
| WO-2019200273-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177883-A1 | Antisense Oligonucleotides Targeting ATXN3 | ATXN2, ATXN2L, ATXN10 | LMNA 280/4885POLB 178/4885ALDH1A1 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.